4//SEC Filing
Grund Nicholas 4
Accession 0001562180-25-000914
CIK 0001517022other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 5:51 PM ET
Size
9.6 KB
Accession
0001562180-25-000914
Insider Transaction Report
Form 4
Grund Nicholas
Chief Commercial Officer
Transactions
- Sale
Common Stock
2025-02-03$2.10/sh−55,621$116,804→ 442,579 total - Award
Stock Option (Right to buy)
2025-01-31+292,300→ 292,300 totalExercise: $2.24Exp: 2035-01-31→ Common Stock (292,300 underlying) - Award
Common Stock
2025-01-31+194,900→ 498,200 total
Footnotes (4)
- [F1]The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
- [F2]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.
- [F3]This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2024.
- [F4]The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
Documents
Issuer
Akebia Therapeutics, Inc.
CIK 0001517022
Entity typeother
Related Parties
1- filerCIK 0001661887
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 5:51 PM ET
- Size
- 9.6 KB